Posts by Sandra Ansanay-Alex
UNIGE Awards 2026 3R Prize for AI Tool Predicting Cancer Metastasis Risk
The prize, presented June 9 at the University of Geneva Faculty of Medicine’s annual ceremony, honors the development of MangroveGS, an AI algorithm that predicts cancer metastasis risk. The University of Geneva has awarded its 2026 3R Prize—recognizing research that reduces, refines, or replaces animal testing—to the team led by Professor Ariel Ruiz i Altaba…
Read MoreImpli Secured £1.4 million from the NIHR
Impli, a deep-tech company spun out of Imperial College London with a presence at Biopôle Lausanne, has just secured £1.4 million from the National Institute for Health and Care Research (NIHR) in the UK, to bring its BEAM biosensor for IVF protocols through first-in-human clinical trials. For the one in six people worldwide affected by…
Read MoreFighting Age-Related Vision Loss: Fribourg Scientists Unlock a Cellular Recycling Key
Age-related macular degeneration (AMD) is one of the leading causes of vision loss in people over 50 across industrialized countries — and as populations age, its prevalence is only set to rise. Scientists at the University of Fribourg may now have found a promising avenue to slow, or even prevent, its progression. The research, led…
Read MoreGivaudan Acquires Eurofragrance
Givaudan, The Vernier-based (Canton of Geneva) global leader in Fragrance & Beauty, announced that it has reached an agreement to acquire a majority stake in Eurofragance, a pure play fragrance house based in Barcelona, Spain. The terms and conditions of the transaction have not been disclosed. Eurofragance is a family-founded fragrance creation house specialising exclusively…
Read MoreSmarter Medicine Challenge
Apply before 21 August 2026 for the Smarter Medicine Association Research Grant and get up to CHF 20,000. The association “smarter medicine – Choosing Wisely Switzerland” is committed to optimising healthcare in Switzerland. The association is inviting applications for a Research Grant. Up to three research projects may be supported, each with a maximum grant…
Read MoreNETRIS Pharma Secures €7.25 Million in EU Horizon Europe Funding
NETRIS Pharma, a clinical-stage oncology company with roots in Lyon since 2008 and a Geneva presence since 2016, has announced the award of €7.25 million under the European Union’s Horizon Europe programme. The funding will support a Phase 2b randomized clinical trial of NP137 in head and neck squamous cell carcinoma (HNSCC). NP137 targets the…
Read MoreTheraPPI closes Pre-Seed Financing Round
TheraPPI, a preclinical biotech company operating both in Lyon (France) and Geneva (Switzerland), announced the second closing of its Pre-Seed financing. The amount has not been disclosed. Current shareholders, PULSALYS, FONGIT and new investors with extensive biotech experience have participated to this financing round. TheraPPI is developing protein interaction-modifying drugs to provide patients with better treatments in…
Read MoreIsomorphic Labs Raises $2.1 Billion to Scale Its AI-Powered Drug Design Engine
Isomorphic Labs, the Google DeepMind spin-off on a mission to “solve all disease” with artificial intelligence, has secured $2.1 billion in Series B funding — one of the largest financing rounds ever seen in the AI drug discovery space. The round was led by Thrive Capital, with significant participation from Alphabet and GV, and joined…
Read MoreOculis Announced Disappointing Results For its OCS-01 Eye Drops
The Vaud-based company, which specializes in neuro-ophthalmology and ophthalmology, stated that the primary endpoint of the DIAMOND trials was not met, leading to the decision not to pursue regulatory approval with the FDA for OCS-01 in the treatment of diabetic macular edema. Despite a well-tolerated safety profile, the lack of significant improvement in visual acuity…
Read MoreTUUS gets CHF 150,000 from Venture Kick
The Vaud-based foodtech startup TUUS has obtained CHF 150,000 from Venture Kick to advance a plant-based hydrogel platform for the controlled release of nutrients and active compounds. The technology aims to provide more stable absorption and improved tolerance in applications ranging from sports nutrition to pharmaceuticals. Endurance athletes often rely on energy gels that cause…
Read More